

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WANJIA GROUP HOLDINGS LIMITED

萬嘉集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 401)

CHANGE OF DIRECTOR

The Board announces that with effect from 15 October 2021, (i) Ms. Yung Ka Lai has resigned as an executive Director; and (ii) Dr. Xiao Zhixin has been appointed as a non-executive Director.

CHANGE OF DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Wanjia Group Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Ms. Yung Ka Lai (“**Ms. Yung**”) resigned from her position as an executive Director with effect from 15 October 2021 so as to allow her to carry out other business commitments.

Ms. Yung has confirmed that she does not have any disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its appreciation for the valuable contribution of Ms. Yung towards the Company during her tenure of service.

The Board would like to further announce that Dr. Xiao Zhixin (“**Dr. Xiao**”) has been appointed as a non-executive Director with effect from 15 October 2021.

The biographical details of Dr. Xiao are as follows:

Dr. Xiao, age 81, has over 50 years of experience in both medical practice and management in the healthcare sector in the People’s Republic of China (the “**PRC**”). He obtained a bachelor’s degree in clinical medicine from Jilin Medical University# (吉林醫科大學) in the PRC in 1964. Since his graduation from the medical school in Jilin Medical University, Dr. Xiao has worked as a medical practitioner in Jilin No. 4 People’s Hospital# (吉林第四人民醫院) until May 2018. From May 2018 to July 2018, Dr. Xiao was a medical practitioner in Jining Rencheng Hanjun Beauty Hospital# (濟寧任城韓駿美容醫院). Dr. Xiao was a medical practitioner in Zhuhai Jiulong Hospital# (珠海九龍醫院) from July 2018 to April 2019. From April 2019 to present, Dr. Xiao is a medical practitioner in Zhuhai Yimei Ladies Medical Beauty Clinic# (珠海伊美名媛醫療美容診所). The Board considers that Dr. Xiao will bring valuable insight for healthcare business of the Group and he will be able to give advice on the best practice for the Group’s hemodialysis service and read into the regulatory and policy of the healthcare system in the PRC.

Dr. Xiao has entered into a letter of appointment with the Company for an initial term of one year commencing from the date of his appointment. He will be entitled to a remuneration of HKD10,000 per month as a non-executive Director. Dr. Xiao is entitled to terminate his appointment at any time by giving the Company one month’s notice in writing. His appointment is subject to normal retirement and re-election by the Shareholders at the annual general meeting of the Company. The remuneration in connection with Dr. Xiao’s position as the non-executive Director will be determined by the remuneration committee of the Company with reference to his duties and level of responsibilities, the remuneration policy of the Company and the prevailing market conditions.

As at the date of this announcement, save as disclosed herein, (i) Dr. Xiao does not hold any other positions within the Group, nor other major appointments and professional qualifications; (ii) Dr. Xiao has no relationship with any Director, member of senior management of the Group or substantial or controlling shareholders of the Company; (iii) Dr. Xiao has not held any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years immediately preceding the date of this announcement; and (iv) Dr. Xiao does not have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)).

Save as disclosed herein, the Board is not aware of any matter in relation to the appointment of Dr. Xiao that needs to be brought to the attention of the Stock Exchange or the Shareholders nor any information to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange.

The Board would like to take this opportunity to extend its warmest welcome to Dr. Xiao on his appointment.

By order of the Board
Wanjia Group Holdings Limited
Wang Jia Jun
Chief Executive Officer and Executive Director

Hong Kong, 15 October 2021

The English transliteration of the Chinese name(s) in this announcement, where indicated with “#”, is included for information purpose only, and should not be regarded as the official English name(s) of such Chinese name(s).

As at the date of this announcement, the Board comprises one executive Director, namely Mr. Wang Jia Jun, one non-executive Director, namely Dr. Xiao Zhixin, and three independent non-executive Directors, namely Mr. Wong Hon Kit, Dr. Liu Yongping and Mr. Ho Man.